The coagulation system as a target for the treatment of human gliomas

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 1, 2002, Pages 19-27

  Ornstein, Deborah L ^a   Meehan, Kenneth R ^a   Zacharski, Leo R ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Coagulation; Glioma; Lovastatin; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; PLACEBO; STATINE DERIVATIVE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; BRAIN TUMOR; CANCER GROWTH; CANCER THERAPY; CLINICAL ARTICLE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION; GLIOMA; HUMANS; NEOPLASM PROTEINS; THROMBOPLASTIN;

EID: 0036189938     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-20561     Document Type: Review

References (76)

1. Cancer statistics, 2001
2. Brain tumors
3. The risk of venous thromboembolism is increased throughout the course of malignant glioma
4. Localization of tissue thromboplastin in the human brain
5. Expression of tissue factor in glioma
6. Expression of tissue factor correlates with grade of malignancy in human glioma
7. 3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression
8. Presence of components of the coagulation and fibrinolysis pathways in situ in malignant glioma tissue
9. Fibrin deposition in primary and metastatic human brain tumors
10. Coagulation alterations in patients undergoing elective craniotomy
11. Serial changes in hemostasis after intracranial surgery
12. Postoperative venous thromboembolism and brain tumors: Part 1. Clinical profile
13. Thromboembolism in patients with high-grade glioma
14. Incidence and risk of thromboembolism during treatment of high-grade gliomas: A prospective study
15. The continuing risk of venous thromboembolism following operation for glioma: Findings from the glioma outcomes project
16. Venous thromboembolism and high grade gliomas
17. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery
18. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery
19. Treatment of cancer with anticoagulants: Rationale in the treatment of melanoma
20. Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells
21. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation
22. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas
23. 2-terminal region of fibrin
24. Tissue factor signalling
25. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation
26. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
27. Tissue factor in cancer angiogenesis and metastasis
28. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
29. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms
30. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review
31. Therapy of venous thromboembolism in patients with brain metastases
32. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis
33. Incidence of recurrent thromboembolism and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: A retrospective analysis
34. The use of heparin for treating human malignancies
35. Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
36. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
37. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
38. Treatment of deep venous thrombosis with low-molecular weight heparins. A meta-analysis
39. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
40. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement
41. Efficacy and tolerability of the novel, oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), compared with standard therapy for the treatment of acute deep vein thrombosis
42. Randomized, double-blind, comparative study of ximelagatran (pINN, formerly 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA)
43. Efficacy and safety of subcutaneous melagatran and oral ximelagatran (pINN, formerly H 376/95) as prophylaxis against thromboembolic complications following general abdominal surgery
44. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities
45. Tissue factor pathway inhibitor: Potential therapeutic applications
46. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
47. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma
48. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients
49. Cyclosporin A inhibits monocyte tissue factor activation in cardiac transplant recipients
50. Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications
51. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor
52. Cancer procoagulant and tissue factor are differently modulated by all-transretinoic acid in acute promyelocytic leukemia cells
53. Anticoagulant effects of synthetic retinoids and activated vitamin D3
54. Induction of differentiation in U-937 and NB4 cells is associated with inhibition of tissue factor production
55. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid
56. Angiotensin II upregulates tissue factor expression by human monocytes
57. Reninangiotensin blockade downregulates tissue factor expression by human endothelial cells
58. Hemostasis imbalance in experimental hypertension. Prevention by zofenopril
59. Non-lipid-related effects of statins
60. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells
61. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis
62. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells
63. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
64. Use of statins and the subsequent development of deep vein thrombosis
65. Antiatherothrombotic properties of statins
66. Treatment with simvastatin and low-dose aspirin lowers thrombin generation and C-reactive protein (CRP) in patients with ischemic heart disease (IHD) and borderline-high cholesterol levels
67. Vastatins inhibit tissue factor expression by human macrophages
68. Simvastatin reduces enhanced monocyte tissue factor expression in patients with type IIa hypercholesterolemia
69. In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin
70. Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells
71. Lovastatin inhibits tissue factor expression by cultured human melanoma cells - A possible explanation for antineoplastic activity
72. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
73. A phase I-II trial of lovastatin for anaplastic astrocyroma and glioblastoma multiforme
74. Lovastatin for the prevention of melanoma: Analysis of AFCAPS/TexCAPS
75. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues
76. 2-terminal fragments derived from fibrinogen and fibrin